Front Row with BioCentury: Inside the turbulent ride of cell and gene therapy

Cell and gene therapy has always promised paradigm-shifting advances, but with that promise comes risks and a roller-coaster of sentiment, especially in 2025. In this episode of Front Row with BioCentury, Executive Director of Biopharma Intelligence Lauren Martz traces how safety setbacks, commercial headwinds, and shifting FDA signals have converged to dampen momentum, even as the underlying scientific potential remains as compelling as ever.

Martz examines why early-stage venture investment in cell and gene therapy has declined, how the next wave of start-ups is responding with platform innovations aimed at reducing manufacturing complexity and cost, and where emerging modalities — including in vivo approaches — are beginning to reset expectations for what’s possible...